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Worldwide, breast cancer (BC) is considered to be the most commonly diagnosed and 
deadly cancer in women, having the majority of deaths resulted from metastatic disease. In 
order to tackle this global problem, it is mandatory to strengthen its preventive, diagnostic and 
therapeutic programs. 
Circulating tumour cells (CTC) have been proposed as a possible approach to depict both 
heterogeneity and dynamics of BC, contributing to a more personalized and holistic patient 
management. CTC are tumour cells shed from both primary tumour and metastasis that can be 
isolated from the bloodstream and analysed by laboratory techniques. 
This work intends to suggest the use of serial evaluation of the quantification and 
qualification of CTC in the management of BC patients, based on a case report of a 40-year 
old woman diagnosed with stage IV luminal B-like BC, managed according to the 
contemporary European guidelines and reaching a 5-year survival. 
On one hand, regarding overall prognosis estimation, CTC analysis have shown its 
potential in better stratifying the already established stages. On the other hand, for follow-up 
assessment, imaging and tumour markers could be upgraded by the addition of serial CTC 
quantification. 
Regarding treatment lines, spatial and temporal cancer cells’ differences and kinetics could 
be better detected and explained by the molecular and numerical analysis of CTC. This would 
contribute not only to understanding general resistance mechanisms, but also to tailoring 
ameliorated therapies. 
To sum up, CTC integrate crucial information of tumour evolution, recurrence and response 
to treatments. In the future, they might play a huge role as adjuvants or substitutes of the current 











Mundialmente, o cancro da mama (CM) é considerado o cancro mais diagnosticado e 
mortal, sendo a maioria desta mortalidade resultado de doença metastática. Para combater este 
problema global, é essencial reforçar os programas de prevenção, diagnóstico e tratamento. 
As células tumorais circulantes (CTC) têm sido propostas como uma possível abordagem 
para retratar a heterogeneidade e dinâmica do CM, contribuindo para uma gestão do doente 
mais personalizada e holística. As CTC são células tumorais provenientes tanto do tumor 
primário como das metástases, que se encontram no sangue periférico e podem ser isoladas e 
analisadas por técnicas laboratoriais. 
Este trabalho pretende sugerir o uso da avaliação seriada da quantidade e qualidade das 
CTC na gestão dos doentes com CM, baseando-se num caso clínico de uma mulher de 40 anos 
diagnosticada com CM, luminal B-like, estádio IV, orientado de acordo com as orientações 
clínicas europeias contemporâneas, atingindo uma sobrevivência total de 5 anos. 
Por um lado, tendo em conta a estimativa de prognóstico, a análise das CTC tem 
demonstrado o seu potencial na melhoria da estratificação dos doentes. Por outro lado, para 
follow-up, os métodos imagiológicos e os marcadores tumorais poderão ser melhorados pela 
adição da quantificação seriada de CTC. 
Relativamente às linhas de tratamento, as diferenças e cinéticas espaciais e temporais das 
células tumorais podem ser melhor detetadas e explicadas pela análise molecular e numérica 
das CTC. Tal contribuirá não só para a compreensão dos mecanismos gerais de resistência, 
como também para o aperfeiçoamento das terapêuticas. 
Resumindo, as CTC integram informação crucial da evolução tumoral, recorrências e 
respostas terapêuticas. No futuro, as CTC poderão vir a ter um papel importante como 
adjuvantes ou substitutos dos métodos correntes de avaliação do CM. O Trabalho Final 























Cancer is one of the leading causes of morbidity and mortality worldwide, accounting for 
9.6 million deaths in 2018 [1]. In 2016, it was responsible for 22% of all non-communicable 
diseases’ deaths, only being exceeded by the cardiovascular group [2]. In addition, breast 
cancer (BC) was found to be the most commonly diagnosed (24,2%) and deadly (15%) cancer 
in women, in 2018, having the majority of deaths resulted from metastatic disease [1, 3]. In 
order to tackle this global problem, it is mandatory to strengthen preventive, diagnostic and 
therapeutic programs of BC, based on its pathophysiology and peculiarities. Nowadays, early 
detection and appropriate patient management (prognosis, treatment and follow-up) are two 
main approaches of oncologic research, where biomarkers are indispensable [4].  
Currently, prognosis estimation and treatment regimens for BC are tailored to its 
phenotypical characteristics - hormonal receptors (HR), human epidermal growth factor 
receptor (HER-2/neu) and tumour-node-metastasis (TNM) stage - which are determined at 
diagnosis, through a primary tumour biopsy and imaging [5, 6]. However, BC is a spatial and 
temporal dynamic disease, evolving through the Darwinian theory of natural selection, and thus 
originating a wide genomic heterogeneity inter- and intra-tumour site. This selection is 
enforced by the tumour microenvironments and drugs, originating resistance and disease 
recurrence [7]. Therefore, the initial evaluation of a neoplasia might underestimate its 
complexity and instability, inducing wrong therapeutic decisions and predictions.  
In this context, circulating tumour cells (CTC) have been proposed as a possible approach 
to face this heterogeneity and dynamics, and so, to offer a more targeted and personalized 
patient management. CTC are tumour cells (single or in clusters) found in the bloodstream, 
shed from both primary tumours or metastases. CTC play a huge role in tumour progression, 
metastatic spread and the interaction between diverse cancerous sites along the body [8].  
Numerous techniques have been developed in order to isolate CTC from venous blood 
samples and analyse their clinical worthiness. Nowadays, CellSearch technique is the only 
Food and Drug Administration (FDA) approved [9, 10]. CTC are integrated in the so-called 
“liquid biopsy”, alongside other circulating tumour products (CTP) such as circulating cell-
free tumour DNA (ctDNA) and RNA [11]. Overall, they offer a minimally invasive and real-
time method of evaluating heterogeneity, throughout tumour evolution and treatment [7]. In 
fact, the superiority of these “liquid biopsies” over solid biopsies, radiological imaging and 
serum tumour markers – carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) 
– is being investigated [10, 12, 13].  
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Moreover, CTC have demonstrated their potential in the clinical management of both early 
and metastatic BC patients, concerning not only their quantity, but also their quality. In general, 
the prognostic value of CTC at baseline and follow-up seems independent of cancer subtype, 
except for the amplificated HER-2/neu subtype where a selective action of anti-HER-2/neu 
therapies against CTC has been reported [14, 15]. 
Firstly, in early BC, the presence of CTC was significantly associated with decreased 
disease-free survival (DFS) and overall survival (OS) [16]. Also, their persistence after 
adjuvant chemotherapy significantly reduced DFS [17]. 
Secondly, in metastatic BC, a baseline ³5 CTC/7.5mL of blood was significantly associated 
with an increased number of metastatic sites and shorter progression-free survival (PFS) and 
OS [18, 19]. Additionally, after chemotherapy, patients with ³5 CTC/7.5mL still had 
significantly worse clinical benefit rate, PFS and OS. Further, if a baseline ³5 CTC/7.5mL 
dropped to <5 CTC/7.5mL after chemotherapy, OS would become similar to those who already 
had <5 CTC/7.5mL [20]. 
Furthermore, in order to metastasise, the primary tumour cells must undergo a type 3 
epithelial-to-mesenchymal transition (EMT), leading to motile and aggressive tumour cells that 
enter circulation [21]. Modifications are induced by reactive stroma and hematogenous factors, 
and reversed in the micro-metastatic places [11, 22]. Thereby, CTC’s features change overtime, 
originating a continuum of phenotypes from epithelial to epithelial-mesenchymal, 
mesenchymal and stem-like [23]. In fact, EMT markers (vimentin, TWIST1) occur more 
frequently in metastatic than early BC and the mesenchymal and stem-like phenotypes have 
been correlated with non-responders to therapy [24, 25]. 
In the future, molecular analysis of CTC may allow the detection of tumour advantageous 
characteristics and heterogeneity, associated with tumour aggressiveness, worse prognosis, 
treatment resistance and disease recurrence. This would contribute not only to research and the 
understanding of cancer, but also to identify crucial biomarkers throughout cancer progression, 
which could be quantified and targeted and, consequently, ameliorate patient evaluation and 
management. 
Finally, this work intends to discuss the usefulness of CTC in BC patients, based on a case 
report of a 40-year old woman diagnosed with stage IV luminal B-like breast cancer and 
managed according to the contemporary European guidelines, where the addition of serial 





The following clinical case was described based on the consultation of the patient’s medical 
process, from the Oncology Department of Hospital Santa Maria, Lisbon, Portugal. 
 
Female, 40 years old, Caucasian, administrative worker, autonomous on her daily life and 
apparently healthy. She had taken oral contraceptives for 10 years and never gave birth or 
breastfed. On a familial note, her aunt suffered from BC. More importantly, she was being 
investigated for cutaneous thickening and nipple retraction on her left breast, not yet diagnosed. 
 In December 2011, the patient presented to her general practitioner complaining of a 
continuous low back pain, with no accompanying symptoms. A lumbosacral spine X-Ray 
showed no evidence of lesions. However, a lumbar CT scan from January 2012 detected 
multiple lithic lesions on the vertebral bodies of D12, L1, L2, L3, L4, sacrum and both iliac 
bones, not affecting the surrounding soft tissues nor the spinal canal. Being most likely of 
secondary nature, the patient was referred to an oncologist. 
 
Oncologic Clinical Examination (January 2012) 
Patient presented with difficult and painful mobilization, with no evidence of medullary 
compression. Left breast showed cutaneous thickening, nipple retraction and hardness behind 
the nipple. Left axilla had a fixed and hard adenopathy (level 1). No other alterations regarding 
right breast, other lymph nodes, abdominal and thoracic examination. 
 
Mammography, Ultrasonography and Biopsies (February 2012) 
Left breast showed an individualized dense region behind the nipple, of 7,7 mm, 
heterogenous and stellate, conditioning invasion, thickening and retraction of it, without clear 
constitution of nodules nor microcalcifications. Histologically, the tissue was classified as an 
invasive ductal carcinoma (IDC), grade II, with positive oestrogen receptor (ER), positive 
progesterone receptor (PR), high ki-67, negative p53 and no HER-2/neu amplification (BI-
RADS 6). Right breast showed only diverse microcystic formations (BI-RADS 2). Left axilla 






Thoracic, Abdominal and Pelvic (TAP) CT Scan (February 2012) 
Lithic bone lesions were found in all vertebral spine and iliac bones, with aggressiveness 
evidenced by cortical ruptures. There was a pathological fracture of a left medium rib. Normal 
sized liver showed a 2 cm hypodense nodule in the left lobe. No other abnormalities. 
 
Bone Scan (February 2012) 
There was focal hyperfixation of the radioactive drug at L1-L2. Less intensity was seen at 
D11, D12, two right ribs, one left rib, left iliac bone and right trochanteric region. Alterations 
corresponded to multiple metastases. 
 
To sum up, in February, patient was diagnosed with stage IV, luminal B-like, IDC on her 
left breast, which had already metastasized to her left axillary lymph nodes and axial and 
appendicular skeletons. 
Endocrine therapy (ET) with Tamoxifen [20 mg per os (PO) daily] and Goserelin Acetate 
[10,8 mg subcutaneous (SC) every 12 weeks] were proposed. In addition, Zoledronic Acid [5 
mg intravenous (IV) monthly], palliative Radiotherapy (RT) [30Gy/10fr regimen] on the 
affected bone areas and an Orthopaedic vest were prescribed. Every treatment was well 
tolerated, with only mild and non-pharmacologically treated gastrointestinal toxicity. 
After RT (March), patient presented better, with less pain and no analgesics needed. 
Analytically, CA 15-3 had decreased from 273 (February) to 213 U/mL (March). TAP CT Scan 
confirmed no new metastasis. 
In August, patient was submitted to a successful radical left Mastectomy with lymph node 
dissection. Surgical management of bone metastasis was not considered adequate. 
Until December, patient felt good [performance status (PS) 0-1]. Regarding tumour 
markers: CA 15-3 decreased from 273 (February) to 45,5 U/mL (October) and CEA had been 
stable, between 0,5-1,6 ng/mL. However, follow-up imaging showed disease progression. 
 
Bone Scan (December 2012) 
Heterogeneity was found, with focal hyperfixation on D5, D6, D8, D10, right and left ribs, 
both scapulae-humeral joints, both ischia, pubic symphysis and right trochanteric region. This 





Lumbar CT Scan (December 2012) 
Mixed (lithic and blastic) lesions were seen in almost all vertebrae, sacrum and iliac bones, 
associated with cortical ruptures and soft tissue components. There were pathological collapses 
of C7, D5 and L2, with discrete posterior and intracanal deviation. No evidence of spinal 
compression. 
 
Consequently, in January 2013, Tamoxifen was replaced by Letrozole (2,5 mg PO daily). 
Until April, there was stabilization of both tumour markers: CEA between 0,5-0,7 ng/mL 
and CA 15-3 between 45,1-50,2 U/mL; followed by a decrease in CA 15-3 from 45,9 (April) 
to 18,8 U/mL (February 2014). 
Clinically, patient was asymptomatic (PS 0) and waiting for breast reconstruction surgery. 
Mild and reversible paraesthesia on both arms was described but not translated into imaging 
medullary compression. 
 
Spinal MRI (July 2013) 
Diffuse and heterogenous metastatic lesions were found, being larger in C7, D1, D5, D8 
and D12, and diffuse in the lumbar segment, sacrum and iliac bones. They were more expressed 
in D5 and L2, with reduction of the vertebral bodies’ height and anterior involvement of the 
dural sac. Incipient anterolisthesis of L5 over S1 and degenerative alterations in the cervical 
vertebral discs were identified. No other abnormalities. 
 
Until April 2014, patient remained asymptomatic. Follow-up exams were incoherent and 
tumour markers were not increasing. Thereby, no change in endocrine therapy was described. 
Only Zoledronic Acid posology was altered to 5 mg every 3 months in February. 
 
Bone Scan (January 2014) 
There was maintenance in the distribution and metabolism of bone involvement in D5, D6, 
D8, D10, right and left ribs, both scapulae-humeral joints, both ischia, pubic symphysis and 
right trochanteric region. There was a discrete and focal increase of intensity in L1, L2, left 
sacral wing and right femoral head, which was attributed to new secondary lesions. 
 
Pelvic CT Scan (April 2014) 
Multiple and diffuse metastatic lesions were seen in the same areas as before, having central 
osteolysis and peripheral sclerosis, being heterogenous and with unclear borders, namely in the 
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left acetabular and supra-acetabular areas. These changes were considered inherent to 
treatment, which hindered comparative studies. No new lesions. 
 
In October, patient restarted the low back pain, which was controlled by analgesics. Clinical 
examination was clear. However, CA 15-3 had been slightly increasing: 21,6 (March) to 28,9 
(July) to 34,6 (November) to 52,4 U/mL (February 2015). 
Chest X-Ray (November 2014), superior abdominal Ultrasound (December 2014), Bone 
Scan (December 2014), spinal MRI (March 2015) and pelvic CT Scan (March 2015) showed 
no new lesions. In addition, no deleterious mutations were detected in BRCA 1 or 2 by 
sequencing and quantitative PCR analysis (March 2015). 
Consequently, therapy was maintained. 
In February 2015, patient successfully finished all left breast reconstructive surgeries. 
In May, patient complained of sporadic mechanical pain which was extinguished by 
analgesics. Clinical examination was unremarkable. However, CA 15-3 (61 U/mL) and total 
bilirubin (value not shown) had been increasing, with no changes in the liver enzymes. 
 
Superior Abdominal Ultrasound (June 2015) 
Liver was normal sized, regular and homogenous. There were some hypoechogenic and 
solid nodules, the biggest one of 2,7 cm and localized in the right lobe periphery. Smaller 
nodules were seen in the right (two) and left (one) lobes. Changes were suspicious of hepatic 
metastasis. In addition, cystic formations remained (maximum 2 cm). No other abnormalities. 
 
Thereby, Letrozole was replaced by Fulvestrant [500 mg intramuscular (IM) monthly]. 
Patient remained asymptomatic and thoracic CT (July 2015) and Bone Scan (August 2015) 
showed no significant changes. However, CA 15-3 was increasing (225 U/mL in November).  
 
Superior Abdominal Ultrasound (November 2015) 
Diffuse hepatic lesions had become greater in number and dimension. The greater one was 
central (segments IV-V) with 5x4,3 cm and the previous 2,7 cm lesion had 3,8 cm. New 
multiple nodules varied between 1,5-2,0 cm. Cystic formations seemed stable. No other 
abnormalities. 
 
ET was discontinued. A Doxorubicin/Cyclophosphamide 5-cycles regimen was prescribed, 
from November 2015 to March 2016. Initially, patient suffered from grade 1 toxicities 
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(neutropenia, mild infections, fever), so, concomitant Filgrastim (G-CSF) was prescribed, 
achieving tolerance. After the last cycle, patient still complained of anorexia, asthenia and 
abdominal discomfort, having been diagnosed with febrile neutropenia, admitted to the hospital 
and completely recovered. 
Overall, CA 15-3 decreased from 263 (December) to 147 (January) to 97 U/mL (February). 
However, imaging showed only partial favourable response. 
 
Superior Abdominal Ultrasound (March 2016) 
Previous solid nodular images were no longer identified. In the right lobe, a calcified 
formation of 1,3x1,2 cm and another with an hypoechogenic periphery and a fibrotic zone were 
seen. In the left lobe, cystic images of 2 and 1,5 cm were described. No other abnormalities. 
 
In April 2016, 8-cycle Paclitaxel regimen was started. However, grade 1 toxicity (afebrile 
neutropenia) was seen, forcing treatment with G-CSF and postponement of the following 
cycles, finishing only in July. 
Clinically, the patient was asthenic and complained of haemorrhoids, that were not 
thrombosed nor infected. Symptomatic measures were taken. In May, patient showed facial 
asymmetry and slower speech which spontaneously reversed. 
Nevertheless, CA 15-3 increased from 135 (April) to 152 U/mL (May), demanding new 
imaging studies. Superior abdominal Ultrasound (June/2016) was similar to previous one. 
 
Bone Scan (July 2016) 
There was heterogeneity along the spine, individualizing multiple hyperfixations in D3, 
D4, D5, D10, D11, D12, L3, bilateral ribs, sternum, both iliac bones and right trochanteric 
region. Heterogenous distribution in the humeral heads showed incipient metastasis. 
Comparatively, there were no new lesions and metabolic activity was diminished, meaning 
improvement. 
 
TAP CT Scan (July 2016) 
Multiple macronodular images were seen in the hepatic parenchyma, meaning multiple 
secondary lesions involving diverse liver segments. The dominant nodules rested in segments 
IV B (3 cm) and VI/V (6,2 cm), with coarse calcifications. No other abnormalities. 
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A new line of chemotherapy was proposed: a 4-cycle Capecitabin regimen from August to 
November. The first two cycles were badly-tolerated with grade 1 haematological 
(neutropenia) and grade 2 gastrointestinal (colitis) toxicities. Thereby, the last two cycles were 
performed with dose reduction. 
 
Superior Abdominal CT Scan (November 2016) 
In the right hepatic lobe, previous solid and hypodense images with intralesional 
calcifications showed discrete reduction. 
 
Even tough, last CT scan showed slight progress, in December, CA 15-3 and CEA 
increased to 113 U/mL and 10,2 ng/mL, respectively. 
Concomitantly, patient showed up with a painful and oedematous trajectory of her right 
external jugular vein, which was examined by the vascular surgery department, being 
diagnosed as a superficial thrombosis. No other venous thrombosis was detected. Patient was 
successfully treated with Tinzaparin (during 18 days). 
 
Superior Abdominal CT Scan (February 2017) 
There had been a growth of the previous hepatic nodules. The most predominant one was 
localized in the right lobe, having 5,6 x 6,5 cm. 
 
Furthermore, CA 15-3 and CEA increased to 251 U/mL and 15 ng/mL, respectively. 
Thereby, treatment was changed to Vinorelbine, every 2-3 weeks, until May. 
In March, Bone Scan overlapped the previous one. 
In April, patient’s CTC were isolated from a whole blood sample (7,5 mL) by being 
processed through a microfluidic device, immunostained and analysed as follow: 
× Total: 1091 CTC/7,5 mL; 
× Epithelial (DAPI+/CD45-/CK+/Vim-): 679 CTC/7,5 mL; 
× Epithelial-mesenchymal (DAPI+/CD45-/CK+/Vim+): 310 CTC/7,5 mL; 
× Mesenchymal (DAPI+/CD45-/CK-/Vim+): 102 CTC/7,5 mL. 
 
At this time, patient complained of lumbar pain, irradiating to the abdomen and inferior 
limbs and conditioning body rotation and mobilization. No other complaints. Patient was 
symptomatically treated, achieving PS 1. 
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Analytically, LDH was high (328 UI/L), GGT was increasing (120 to 174 U/L, in one week) 
and the tumour markers were also increasing (CA 15-3 from 549 to 694 U/mL and CEA from 
17,5 to 21 ng/mL, in one week). 
 
Lumbar MRI (April 2017) 
Diffuse secondary infiltration of bone marrow with expansive lesion on L2, affecting the 
cauda equina roots and conditioning hypersignalling of the medullary cone. There was another 
lesion conditioning a bulging of the posterior wall, with soft tissue component but no evident 
involvement of the spinal cord. 
 
Superior Abdominal CT Scan (May 2017) 
Liver had multiple focal lesions (cystic, necrotic and calcified), that grew in number and 
dimension. The dominant lesions were in segment V (7,1 cm), IV B (4,6 cm) and VIII (4,2 
cm). Bone metastasis were also seen in all vertebral bodies, having important blastic expression 
and less lithic one, with deformation of L1-L2; and in both iliac bones, being sclerotic and 
more developed than the previous exam. 
 
In May, patient referred episodes of paraesthesia on both inferior limbs and pain on her 
right hip. Thus, palliative Radiotherapy (20Gy/5fr regimen) was prescribed on L1-L3, right 
femoral head and neck. Only abdominal discomfort was stated, not demanding treatment. 
On physical examination, a hard and posterior cervical lymph node was found. 
 
Cervical Ultrasound and Biopsies (June 2017) 
Thyroid parenchyma showed multiple nodules on both lobes, namely one in the inferior 
right lobe, of 14 mm, heterogenous, hypoechogenic and irregular, suggesting a need for 
histological characterization. On the right cervical level V, there was a solid heterogenous 
nodule of 17x15x20 mm, between the muscles, possibly a secondary lesion. No other 
abnormalities. Biopsies confirmed metastasis on the inferior right thyroid and right level V 
lymph node. 
 
Moreover, CA 15-3 was evaluated at 1700 U/mL. 
Therefore, a 4-cycle Docetaxel/Gemcitabine regiment was initiated in June, lasting until 
August. First cycle conferred grade 1 toxicities, forcing dose reduction and addition of 
Filgrastim to the next cycles. 
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Clinically, patient complained of asthenia, anorexia, general discomfort, myalgias and 
headaches. Patient was, also, diagnosed and treated for several respiratory infections. 
In June, a 1-week dull epigastric pain, without irradiation, associated with microcytic 
anaemia (Hb 8,1 g/dL) and elevated liver enzymes (GGT 752 U/L), was diagnosed as an upper 
gastrointestinal haemorrhage and treated appropriately. 
Until September, patient came repeatedly to the hospital with several complains of 
obstipation, abdominal pain, abdominal distension, difficulty breathing and fever. Clinical 
examination confirmed ascites, inferior limbs’ oedema and diminished respiratory sounds. 
Analytically, patient remained pancytopenic, PCR and CK were elevated and albumin was low. 






The previous case report represents a typical and adequately managed patient with stage IV 
luminal B-like BC, at diagnosis. Overcoming the median overall survival (3 years), the patient 
integrated the 25% that reach a 5-year survival [26]. 
Regarding treatment lines and follow-up assessment, most ESO-ESMO recommendations 
were respected. Firstly, haematology, biochemistry, tumour markers and imaging of the chest, 
abdomen and bone were serially performed in order to evaluate general status, response to 
treatment and disease progression. Painful and neurological symptoms were constantly deeply 
analysed. Secondly, removal of the primary tumour, ovarian function suppression, ET, 
chemotherapy and bisphosphonate regimens resembled the ESO-ESMO guidelines, being 
always adapted to the patient and to the primary tumour biopsy. In addition, never did a tumour 
marker alteration alone drive a change in treatment [26, 27]. Overall, patient management is 






In this case report, initial prognosis estimation was based on TNM stage (IV) and biopsy 
phenotype (IDC, luminal B-like, malignancy grade II), which could have been complemented 
by the quantification and qualification of baseline CTC, contributing to a better stratification 
and evaluation of the patient inside the metastatic group [18, 19].  
Nevertheless, follow-up assessments were based on imaging (TAP CT scan, bone scan and 
ultrasound) supplemented by the progression of BC tumour markers (CA 15-3 and CEA). 
However, CTC have appeared to not only correlate with radiographic determinations of disease 
progression, but also to be more accurate and reproducible, having an inter-reader variability 
of 1% versus 15%, a short half-life (1-2.4h) and no radiation exposure – for a standard adult, 
each TAP CT scan and bone scan equals to 10 and 4 mSv of radiation, respectively [11, 12, 28, 
29, 30]. CellSearch has shown to be associated with high intra- and inter-observer as well as 
inter-instrument accordance [31]. Also, even though the superiority of CTC over serum tumour 
markers (CEA and CA 15-3) has not yet been reported, it is known that the later carry not only 
therapy-related surges, but also limited specificity and sensibility (80% when combined, at first 
progressive disease), possibly skewing management [13, 32, 33]. Thereby, comparative and 
cost-effective studies between current methods and CTC must be carried on. 
Nowadays, metastases’ biopsies might be proposed, as to reassess biomarkers (ER, PR and 
HER-2/neu), embrace tumour dynamics and heterogeneity and, possibly, guide alterations of 
the targeted therapy [26]. In fact, discordances between the primary breast tumour and its 
metastasis have been shown to be as frequent as up to 40% for the HR and 10% for HER-2/neu, 
leading to worse outcomes and changes in treatment in 14% of patients [34]. However, solid 
biopsies are invasive and not always possible, while liquid biopsies offer an easier alternative, 
which overcome the problem of scarce tumours and allow serial monitorization [7]. Yet, CTC 
are rare, so their detection is still challenging, and they might fail to detect co-existing intra-
tumour clones, deviating and lessening therapy [8]. 
Thereby, in this case report, serial immuno-phenotyping of CTC could have been an 
adequate alternative to depict both inter and intra-tumour heterogeneity, analyse de novo 
modifications of tumour targets, recognize resistance mechanisms and drive treatment lines. 
Decision making could have considered the possible negativation of the HR, providing ET 
resistance, and the possible amplification of HER-2/neu in the cancer stem cell (CSC) 
population, providing aggressiveness [27, 35]. These could explain the bone and hepatic 
disease progression concomitant to the three lines of ET (Tamoxifen, Letrozole and Fulvestrant 
from 2012 to 2015), suggesting ET inefficiency. In addition, adjuvant anti-HER-2/neu drugs 
(e.g. Transtuzumab) could have been a possible approach to tackle recurrence. 
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Furthermore, one possible use for CTC enumeration and kinetics is the early evaluation of 
chemotherapy effectiveness and patient prognosis, since, after the first cycle, a CTC status of 
< 5/7.5 mL of blood or its reduction to it is highly predictive of a better outcome [17, 20, 36]. 
Indeed, a better evaluation of chemotherapy efficiency would benefit treatment decisions, 
sparing patients of unnecessary cycles/regimens and their inherent side effects, such as the 
constitutional, haematological, infectious and gastrointestinal toxicities reported in the case 
report [37]. However, changing regimens based on the failure of reducing CTC did not seem 
to change OS, suggesting chemo-resistance and a need to opt for different approaches [10]. 
Therefore, an investment in future trials to identify the most adequate management decision 
regarding a post-chemotherapy persistence of high-level CTC should be carried on. 
In April 2017, 1091 CTC/7,5mL were collected and analysed from the patient’s blood. 
Using CellSearch, CTC have been detected in nearly 60% of metastatic BC, with a median 
value of 2 CTC/7.5mL [38, 39]. Higher numbers have been found in patients with positive ER, 
multiple bone or both bone and visceral metastasis [39, 40]. Indeed, this is concordant with the 
high CTC level seen in this case report, making feasible their extraction and molecular/genomic 
characterization. Also, at this time, the patient had already been submitted to three lines of ET 
and four regimens of chemotherapy, thus >5 CTC/7.5mL of blood represented a significantly 
worse clinical benefit rate, PFS and OS, and previous treatments’ inefficiency [20]. However, 
the lack of serial CTC evaluations makes it impossible to make greater conclusions as a 
patient’s CTC history and dynamics (throughout treatments) would better reflect the overall 
aggressiveness and prognosis of that BC than a current CTC status alone [36]. 
Regarding the EMT continuum, the patient had 679 epithelial, 310 epithelial-mesenchymal 
and 102 mesenchymal CTCs/7,5mL of blood. Indeed, luminal-like BC are mainly 
characterized by epithelial CTC, which have also been associated with bone and hepatic (in 
contrast to CNS) metastasis, as observed [41, 42]. Additionally, EMT markers are shown in 
38% of the CTC collected, maybe representing a switch to a mesenchymal predominant 
phenotype, justifying disease progression, treatment resistance and worse outcome [8, 38]. 
Interestingly, drugs targeting the EMT and stemness pathways (e.g. Everolimus for the 
PIK3/Akt/mTOR pathway) are possible approaches to resistant BC [26]. Serial evaluations of 
CTC’s EMT markers during patient evolution could grant crucial and beneficial information. 
In this context, most CTC’s isolation techniques enrich and identify cells by their 
expression of epithelial markers (EpCAM, CK), underestimating the mesenchymal group [10]. 
In fact, refinement and optimization of this detection is important for future uses. 
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Overall, the handicaps of CTC usage during BC management rely on their rarity in the 
bloodstream, markers’ heterogeneity and our uncertain scientific knowledge towards their 
biological function, clinical utility and economic impact [8, 10, 43]. 
To sum up, this work proposes the usage of serial CTC enumeration and characterisation 
to better define prognosis, recurrence and treatment efficiency. Recognition of their utility not 
only in the understanding of general cancer mechanisms, but also in the optimal patient 
management is the first step to motivate future investments and researches. Indeed, CTC look 
forward to upgrade BC guidelines, as adjuvants or substitutes of the current follow-up methods 
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